Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (HK:2252)
:2252
Top Page
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
(2252)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$30.00
▲(13.38% Upside)
Action:UpgradedDate:01/15/26
The score is held down primarily by weak financial performance, especially persistent losses and negative operating/free cash flow, alongside leverage risk. Technicals are a positive offset with strong trend and momentum, while valuation support is limited due to negative earnings and no dividend data.
Positive Factors
Rapid revenue growth
Sustained triple-digit revenue expansion signals strong adoption of MedBot's robotic systems and instruments, providing a larger recurring revenue base. Over the medium term this top-line momentum can fund scale efficiencies, R&D and commercialization if margins improve.
Negative Factors
Negative operating and free cash flow
Persistent negative operating and free cash flow constrains internal funding for production scale, service rollout and R&D. Over months this forces reliance on external financing, increasing dilution or interest burden and limiting the firm’s financial flexibility to execute growth plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid revenue growth
Sustained triple-digit revenue expansion signals strong adoption of MedBot's robotic systems and instruments, providing a larger recurring revenue base. Over the medium term this top-line momentum can fund scale efficiencies, R&D and commercialization if margins improve.
Read all positive factors
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$27.29B
Dividend YieldN/A
Average Volume (3M)5.91M
Price to Earnings (P/E)―
Beta (1Y)2.14
Revenue Growth112.97%
EPS Growth37.70%
CountryHK
Employees450
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.15
Shares Outstanding1,024,730,800
10 Day Avg. Volume5,228,361
30 Day Avg. Volume5,906,894
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)31.04
Price to Sales (P/S)33.57
P/FCF Ratio-25.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$36.50Price Target Upside37.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.01
Revenue Forecast (FY)HK$1.02B
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic...
How the Company Makes Money
The company generates revenue primarily through the sale of its robotic surgical systems and associated instruments, which are sold to hospitals and surgical centers. Key revenue streams include upfront sales of robotic systems, recurring revenue ...
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
50
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 333.70M | 257.25M | 104.59M | 21.60M | 2.15M | 0.00 |
| Gross Profit | 110.71M | 86.22M | 14.69M | 6.56M | 919.00K | 0.00 |
| EBITDA | -275.57M | -413.34M | -893.36M | -1.05B | -543.84M | -160.93M |
| Net Income | -478.60M | -642.41M | -1.01B | -1.14B | -582.92M | -208.87M |
Balance Sheet | ||||||
| Total Assets | 1.50B | 1.28B | 1.43B | 1.93B | 2.79B | 1.70B |
| Cash, Cash Equivalents and Short-Term Investments | 815.79M | 612.23M | 507.71M | 747.96M | 1.94B | 1.50B |
| Total Debt | 668.22M | 691.33M | 560.42M | 219.95M | 204.68M | 19.24M |
| Total Liabilities | 985.94M | 1.02B | 926.15M | 522.25M | 401.73M | 262.90M |
| Stockholders Equity | 535.11M | 278.20M | 519.48M | 1.42B | 2.39B | 1.44B |
Cash Flow | ||||||
| Free Cash Flow | -233.38M | -340.21M | -634.30M | -1.09B | -674.47M | -118.05M |
| Operating Cash Flow | -205.18M | -298.12M | -567.84M | -898.48M | -540.49M | -103.04M |
| Investing Cash Flow | -32.22M | -47.60M | -58.38M | -267.82M | -396.57M | -15.01M |
| Financing Cash Flow | 833.81M | 449.96M | 385.68M | -27.95M | 1.39B | 1.56B |
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Technical Analysis
Positive
26.46
Price Trends
26.39
Positive
24.93
Positive
23.98
Positive
Market Momentum
0.03
Negative
54.80
Neutral
75.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2252, the sentiment is Positive. The current price of 26.46 is above the 20-day moving average (MA) of 24.77, above the 50-day MA of 26.39, and above the 200-day MA of 23.98, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 54.80 is Neutral, neither overbought nor oversold. The STOCH value of 75.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2252.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$7.21B | 17.31 | 11.91% | 1.26% | 25.18% | 55.79% | |
69 Neutral | HK$6.32B | 31.02 | 11.84% | 1.50% | -5.18% | -9.69% | |
57 Neutral | HK$7.86B | 36.52 | 1.98% | ― | 3.42% | -70.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$27.29B | -91.69 | -117.51% | ― | 112.97% | 37.70% | |
46 Neutral | HK$17.58B | -9.88 | -26.71% | ― | -1.04% | 60.66% | |
43 Neutral | HK$3.69B | -218.71 | 0.22% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
26.46
12.82
93.99%
HK:0853
MicroPort Scientific
9.17
2.61
39.79%
HK:1302
LifeTech Scientific Corporation
1.82
0.51
38.93%
HK:1789
AK Medical Holdings Ltd.
6.43
1.11
20.86%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.90
-0.90
-23.68%
HK:2172
MicroPort NeuroTech Limited
10.81
1.72
18.92%
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Corporate Events
MicroPort MedBot Gains CSRC Nod for 5.99 Million H-Share Conversion
Feb 4, 2026
Shanghai MicroPort MedBot received CSRC approval to convert 5,989,798 previously unlisted shares held by two shareholders into H shares, representing about 0.58% of its total share capital, paving the way for trading on the Hong Kong Main Board pe...
MicroPort MedBot Forecasts Revenue Surge and Sharply Narrowed Loss on Toumai Robot Boom
Jan 21, 2026
Shanghai MicroPort MedBot expects its 2025 revenue to grow by about 110% to 120% year on year, driven primarily by breakthrough commercialization of its flagship Toumai laparoscopic surgical robot. Toumai has gained strong traction overseas, secur...
MicroPort MedBot Wins NMPA Approval for UniPath Bronchoscopic Surgical Robot
Dec 24, 2025
Shanghai MicroPort MedBot (Group) Co., Ltd. has obtained approval from China’s National Medical Products Administration for its self-developed UniPath Electronic Bronchoscopic Surgical Robotic System, a non-invasive natural orifice platform ...
MicroPort MedBot’s Toumai Surgical Robot Surpasses 100 Global Commercial Installations
Dec 24, 2025
Shanghai MicroPort MedBot announced that cumulative orders for its core robotic surgery products have surpassed 230 units, with its flagship Toumai laparoscopic surgical robot accounting for more than 160 commercial orders globally and ranking amo...
Shanghai MicroPort MedBot Strengthens Audit Committee Governance
Nov 25, 2025
Shanghai MicroPort MedBot (Group) Co., Ltd. has established terms of reference for its Audit Committee to enhance decision-making and oversight processes. The Audit Committee is tasked with supervising internal and external audits, ensuring effect...
Shanghai MicroPort MedBot Enhances Governance with New Nomination Committee
Nov 25, 2025
Shanghai MicroPort MedBot (Group) Co., Ltd. has established a Nomination Committee under its board of directors to enhance corporate governance and streamline the appointment process for directors and senior management. This move aims to optimize ...
Shanghai MicroPort MedBot Enhances Corporate Governance with New Committee
Nov 25, 2025
Shanghai MicroPort MedBot (Group) Co., Ltd. has established a Remuneration and Appraisal Committee under its board of directors to enhance corporate governance. This committee is responsible for formulating appraisal standards and reviewing remune...
Shanghai MicroPort MedBot Establishes Strategy and Development Committee
Nov 25, 2025
Shanghai MicroPort MedBot (Group) Co., Ltd. announced the establishment of a Strategy and Development Committee under its board of directors. This committee is tasked with researching and proposing long-term development strategies and major decisi...
Shanghai MicroPort MedBot Announces Key Appointments and Governance Changes at 2025 EGM
Nov 25, 2025
Shanghai MicroPort MedBot (Group) Co., Ltd. held its 2025 Extraordinary General Meeting (EGM) on November 25, 2025, where several key resolutions were passed. These included the appointment of new directors and amendments to the Articles of Associ...
Shanghai MicroPort MedBot Announces EGM for Board Appointments and Governance Amendments
Nov 5, 2025
Shanghai MicroPort MedBot (Group) Co., Ltd. has announced an extraordinary general meeting scheduled for November 25, 2025, to discuss several key appointments to its board of directors, including both non-executive and independent non-executive r...
Shanghai MicroPort MedBot Announces Board Reshuffle
Nov 5, 2025
Shanghai MicroPort MedBot (Group) Co., Ltd. announced significant changes in its board of directors, with the resignation of Mr. Sun Hongbin, Ms. Fang Cong, and Dr. Li Minghua, who are stepping down to focus on other business commitments. The comp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.